EntryPoint Capital LLC Has $503,000 Stock Position in Savara Inc. $SVRA

EntryPoint Capital LLC raised its position in Savara Inc. (NASDAQ:SVRA) by 75.9% during the first quarter, HoldingsChannel.com reports. The firm owned 181,655 shares of the company’s stock after buying an additional 78,367 shares during the quarter. EntryPoint Capital LLC’s holdings in Savara were worth $503,000 as of its most recent SEC filing.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the company. Price T Rowe Associates Inc. MD grew its stake in Savara by 13.6% in the fourth quarter. Price T Rowe Associates Inc. MD now owns 43,668 shares of the company’s stock valued at $135,000 after purchasing an additional 5,236 shares in the last quarter. Dimensional Fund Advisors LP grew its stake in Savara by 3.9% in the fourth quarter. Dimensional Fund Advisors LP now owns 143,661 shares of the company’s stock valued at $441,000 after purchasing an additional 5,450 shares in the last quarter. Barclays PLC grew its stake in Savara by 2.5% in the fourth quarter. Barclays PLC now owns 236,705 shares of the company’s stock valued at $728,000 after purchasing an additional 5,700 shares in the last quarter. Farther Finance Advisors LLC grew its stake in Savara by 25.3% in the first quarter. Farther Finance Advisors LLC now owns 32,314 shares of the company’s stock valued at $92,000 after purchasing an additional 6,532 shares in the last quarter. Finally, Algert Global LLC boosted its holdings in Savara by 7.3% in the fourth quarter. Algert Global LLC now owns 132,968 shares of the company’s stock worth $408,000 after purchasing an additional 9,000 shares in the last quarter. Hedge funds and other institutional investors own 87.93% of the company’s stock.

Wall Street Analyst Weigh In

A number of brokerages have weighed in on SVRA. Evercore ISI reduced their price target on Savara from $3.00 to $2.00 and set an “in-line” rating for the company in a research report on Wednesday, May 28th. Oppenheimer lifted their price target on shares of Savara from $5.00 to $6.00 and gave the company an “outperform” rating in a research report on Friday, August 15th. Guggenheim reissued a “buy” rating and issued a $8.00 price target (down previously from $9.00) on shares of Savara in a research report on Wednesday, May 28th. HC Wainwright raised shares of Savara from a “neutral” rating to a “buy” rating and lifted their price target for the company from $2.00 to $5.00 in a research report on Friday, August 15th. Finally, Wells Fargo & Company dropped their price target on shares of Savara from $8.00 to $7.00 and set an “overweight” rating on the stock in a research report on Wednesday, May 28th. Five research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus price target of $6.17.

Savara Trading Up 1.3%

Shares of SVRA opened at $3.09 on Thursday. Savara Inc. has a 12-month low of $1.89 and a 12-month high of $4.70. The company has a quick ratio of 11.08, a current ratio of 11.08 and a debt-to-equity ratio of 0.25. The firm has a market capitalization of $534.08 million, a price-to-earnings ratio of -6.18 and a beta of 0.40. The stock’s 50-day moving average price is $2.44 and its 200 day moving average price is $2.67.

Savara (NASDAQ:SVRA) last released its quarterly earnings data on Wednesday, August 13th. The company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.12) by ($0.02). As a group, research analysts predict that Savara Inc. will post -0.45 earnings per share for the current year.

Insider Buying and Selling

In other news, Director Richard J. Hawkins acquired 48,225 shares of the firm’s stock in a transaction on Friday, June 20th. The shares were purchased at an average cost of $2.04 per share, for a total transaction of $98,379.00. Following the transaction, the director owned 115,466 shares of the company’s stock, valued at approximately $235,550.64. This represents a 71.72% increase in their ownership of the stock. The purchase was disclosed in a filing with the Securities & Exchange Commission, which is available at this link. 5.33% of the stock is currently owned by company insiders.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.